Shire's Elaprase gets Greek distributor

Pharmaceutical Executive Europe, April, 2007 by Anonymous

DISTRIBUTION

Shire (UK) has chosen Samaritan Pharmaceutical (US) to market Elaprase, its treatment for Hunter syndrome, in Greece and Cyprus.

Elaprase (idursulfase) was granted marketing authorization for the longterm treatment of patients with Hunter syndrome by the European Commission in January, having been given the green light in the US in July 2006. It is the only approved enzyme replacement therapy for the disorder.

The treatment will be marketed and distributed by Samaritan on a named patient basis until the pricing and the reimbursement of Elaprase is established in Greece and Cyprus with the relevant regulatory authorities. A launch in those countries is expected by the beginning of the second quarter this year.

Janet Greeson, Samaritan's chief...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.